Marshall Urist - 04 Jun 2021 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role
EVP & Co-Head of R&I
Signature
/s/ Jason Mehar, as Attorney-in-Fact for Marshall Urist
Issuer symbol
RPRX
Transactions as of
04 Jun 2021
Transactions value $
-$1,526,721
Form type
4
Filing time
08 Jun 2021, 20:15:50 UTC
Previous filing
04 Jun 2021
Next filing
11 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPRX Class A Ordinary Shares Sale -$747,661 -16,566 -50% $45.13 16,568 04 Jun 2021 Direct F1
transaction RPRX Class A Ordinary Shares Sale -$779,058 -16,568 -100% $47.02 0 07 Jun 2021 Direct F2
holding RPRX Class A Ordinary Shares 19,020 04 Jun 2021 By IRA
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.37 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.06 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

All reported transactions were effected pursuant to a 10b5-1 plan adopted by the reporting person on March 29, 2021.